ArticleTrends in cancer2016
Novel mechanisms of regulation of miRNAs in CLL.
Article in Trends in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- A Practical Guideline for MicroRNA Sequencing Data Analysis in Chronic Lymphocytic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2025Guideline
- Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Review
- Multiple omics levels of chronic lymphocytic leukemia.Cell death discovery · 2024Review
- miR-769-3p inhibits cellular proliferation of KSHV-infected SH-SY5Y cells through targeting mTOR.Journal of Cancer · 2024Article
- Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia.Frontiers in oncology · 2023Review
- Anti-tumor effect of berberine on chronic lymphocytic leukemia cells.Medical oncology (Northwood, London, England) · 2022Article
- Regulatory role of miRNAs in Wnt signaling pathway linked with cardiovascular diseases.Current research in pharmacology and drug discovery · 2022Article
- A Unified Computational Framework for a Robust, Reliable, and Reproducible Identification of Novel miRNAs From the RNA Sequencing Data.Frontiers in bioinformatics · 2022Article
- Article
- Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers.International journal of molecular sciences · 2021Review
- Article
- Non-Coding RNAs: The "Dark Side Matter" of the CLL Universe.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia.Journal of clinical medicine · 2020Review
- RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome.Blood cancer journal · 2020Article
- Interpreting the MicroRNA-15/107 family: interaction identification by combining network based and experiment supported approach.BMC medical genetics · 2019Article
- MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis.Oncotarget · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
B-cell chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Although, the molecular alterations leading to CLL onset and progression are still under investigation (specifically, the interplay and exact role of oncogenes and tumor suppressors in CLL pathogenesis). MicroRNAs are small non-coding RNAs that regulate gene expression and are expressed in a tissue specific manner. Deregulation of microRNAs can alter expression levels of genes involved in the development and/or progression of tumors. In CLL, microRNAs can function as oncogenes or tumor suppressors. Here, we review the most recent findings on the role of microRNAs in the onset/progression of CLL, and how this knowledge can be used to identify new biomarkers and targets to treat this leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.